🧠 Today is World Brain Day. It reminds us that one of the biggest challenges in brain cancer research isn't only discovering better therapies. It's making sure they reach the tumor. Glioblastoma remains one of the most aggressive brain cancers, with median survival still around 15 months despite surgery, radiotherapy, and chemotherapy. The blood-brain barrier protects the brain, but it also prevents many promising therapies from reaching their target. That's why researchers are increasingly developing glioma-on-chip models that integrate functional BBB components, allowing drug transport and anti-tumor activity to be studied within the same human-relevant platform. At CanChip, this is exactly the kind of challenge we are passionate about solving. Because before asking whether a therapy works, we should first ask: Can it get there? -- 🧠 Are you working on glioblastoma research? Have you explored on-chip technologies to study the blood-brain barrier or tumor microenvironment? We'd love to hear about your experience and the challenges you've encountered.
This is really an exciting development. It is encouraging that cancer researchers are getting human centric data through such cancer chip platforms, specially in aggressive cancers like glioblastoma where drug delivery has remained challenging. Excited to follow CanChip's work!
I really like what your building. Wishing CanChip great success!
Ghazaleh Madani, It's encouraging to see continued efforts on one of the biggest challenges in glioblastoma therapy, to understand how to get them across the blood-brain barrier. It's exciting to see companies like CanChip advancing human-relevant on-chip models, and I'm looking forward to seeing how your BBB-on-a-Chip and tumor-on-chip platforms continue to evolve.